Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.

Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.

<h4>Background</h4>Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Italian market. Very limited post-marketing data exist on the comparative effectiveness of biosimilar and originator ESAs.<h4>Aim</h4>This population-based study was aim...

Full description

Bibliographic Details
Main Authors: Ylenia Ingrasciotta, Francesco Giorgianni, Ilaria Marcianò, Jenny Bolcato, Roberta Pirolo, Alessandro Chinellato, Valentina Ientile, Domenico Santoro, Armando A Genazzani, Angela Alibrandi, Andrea Fontana, Achille P Caputi, Gianluca Trifirò
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155805&type=printable

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155805&type=printable

Similar Items